Goldstein Advisors LLC Buys 7,375 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Goldstein Advisors LLC grew its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 24.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,800 shares of the company’s stock after acquiring an additional 7,375 shares during the quarter. Goldstein Advisors LLC’s holdings in Xeris Biopharma were worth $128,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Xeris Biopharma by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock valued at $9,502,000 after acquiring an additional 93,091 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Xeris Biopharma by 33.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock valued at $3,041,000 after acquiring an additional 342,300 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Xeris Biopharma by 4.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,193,080 shares of the company’s stock valued at $2,684,000 after acquiring an additional 52,074 shares during the last quarter. Walleye Capital LLC acquired a new position in shares of Xeris Biopharma in the 3rd quarter valued at approximately $3,197,000. Finally, Wellington Management Group LLP grew its position in shares of Xeris Biopharma by 11.7% in the 3rd quarter. Wellington Management Group LLP now owns 471,644 shares of the company’s stock valued at $1,344,000 after purchasing an additional 49,535 shares during the period. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Stock Down 1.5 %

NASDAQ:XERS opened at $3.29 on Thursday. Xeris Biopharma Holdings, Inc. has a twelve month low of $1.69 and a twelve month high of $3.87. The business has a 50 day moving average price of $3.34 and a two-hundred day moving average price of $2.97.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Piper Sandler lowered Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research report on Monday, November 11th. HC Wainwright boosted their price objective on Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research report on Monday, November 11th.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.